ArticleRSC advances2025
DNA dendrimer-based nanocarriers for targeted Co-delivery and controlled release of multiple chemotherapeutic drugs.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Versatile DNA-Functionalized Biohybrid Hydrogel Platforms for Electrothermally Activated On-Demand Payload Release.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advancements in nanobiosensors for early cancer detection, challenges, treatment, and future prospects: a comprehensive review.Discover nano · 2026Review
- Rational design of click-assembled chiral dendrimers: anticancer activity and molecular dynamics study.RSC advances · 2026Article
- Tumor microenvironment conversion through intelligent nanomedicine: a paradigm shift in overcoming chemoresistance.Frontiers in oncology · 2026Review
- Astragaloside IV Co-Loaded Osimertinib Liposomes Alleviate EGFR-TKI Resistance in Non-Small Cell Lung Cancer.International journal of nanomedicine · 2026Article
- Nanocarrier-based immunotherapy for viral diseases.International journal of pharmaceutics: X · 2025Review
- A tailored 4GRSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA-based nanomaterials have attracted increasing attention over the past decades due to their incomparable programmability and functionality. In particular, dendritic DNA nanostructures are ideal for constructing drug carriers due to their highly branched structure. In this study, an intelligent drug delivery system was constructed based on DNA dendrimers, in which the DNA duplexes were utilized for simultaneously loading both hydrophilic and hydrophobic small molecule drugs. Additionally, cancer microenvironment-responsive and cancer cell-targeting moieties were introduced into the internal framework and surface of the nanostructures, respectively. Our research shows that these DNA-based drug carriers can enter cancer cells through endocytosis and disintegrate under the reduction of cellular glutathione, thereby achieving targeted co-delivery and controlled release of chemotherapeutic agents and antisense oligonucleotides, providing an effective drug delivery strategy for combined treatment of tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.